[Corrections] Correction to Lancet Oncology 2023; 24: 1029–41

Hurvitz SA, Bardia A, Quiroga V, et al. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. Lancet Oncology 2023; 24: 1029–41—In figure 2B of this Article, the percentage of CCCA has been corrected to 20% for giredestrant and 13% for anastrozole. The appendix has also been corrected. These corrections have been made to the online version as of Oct 31, 2023.